Enjaymo

Sutimlimab-jome (Enjaymo) is a monoclonal antibody that inhibits the classical complement pathway by binding to complement protein component 1 subcomponent s (C1s). This inhibition ultimately prevents hemolysis in patients with cold agglutinin disease (CAD). Sutimlimab-jome (Enjaymo) is FDA-approved for the treatment of hemolysis in adults with cold agglutinin disease (CAD). <a id="